Stifel Reiterates Buy Rating on Illumina (ILMN)

Canaccord Genuity Reiterates Hold Rating on Illumina (ILMN)

Canaccord Genuity analyst Kyle Mikson reiterated a Hold rating and $135.00 price target on Illumina (NASDAQ: ILMN).

The analyst comments "We reiterate our HOLD rating on Illumina (ILMN) shares and maintain our price target at $135. Before the market open on Tuesday, March 4, China's Ministry of Commerce (MOFCOM)... More

Barclays Reiterates Underweight Rating on Illumina (ILMN), PT $100

Barclays analyst Luke Sergott reiterated an Underweight rating and $100.00 price target on Illumina (NASDAQ: ILMN).

The analyst comments "The biggest fear for Tools investors re China tariffs is on how China retaliates. The first shot, indicated weeks ago (see our report HERE, as well as the Reuters article HERE), hits ILMN, with China announcing a ban in effect starting today. On first... More

Evercore ISI Reiterates Outperform Rating on Illumina (ILMN)

Evercore ISI analyst Vijay Kumar reiterated an Outperform rating and $160.00 price target on Illumina (NASDAQ: ILMN)

The analyst comments "Bottomline: Policy uncertainty makes it hard for businesses to investand ILMNs ~40% slide in past month has captured it relative to others. We think ILMN should find support once China news gets priced in. Our Take #1: Assuming zero China revs, EPS HW could be ~50c (assuming no cost actions) As seen from Fig 1, we assumed China OM to be double that of corporate... More

Wolfe Research Reiterates Outperform Rating on Illumina (ILMN), PT $150

Wolfe Research analyst Doug Schenkel reiterated an Outperform rating and $150.00 price target on Illumina (NASDAQ: ILMN)

The analyst comments "Overnight, China banned ILMN from importing sequencers into the country. The company is working to assess the potential impact and continues to... More

Leerink Partners on Illumina (ILMN), 'optics is likely to affect customer willingness to buy'

Leerink Partners analyst Puneet Souda reiterated an Outperform rating and $150.00 price target on Illumina (NASDAQ: ILMN)

The analyst comments "Bottom Line: This morning, China announced a ban on importing ILMN's sequencers. The action is unlikely to come as a surprise and part of retaliatory actions after China placed ILMN on the Unreliable Entity List (UEL) in early February. ILMN kept the China revenue intact after the prior UEL announcements - citing... More

Illumina slides as China bans imports of its gene sequencers

Investing.com -- Shares of Illumina (NASDAQ: ILMN) fell more than 4% in premarket trading on Tuesday after China imposed an immediate ban on the import of its gene sequencing instruments, escalating tensions in the ongoing US-China trade conflict.

Bank of America analysts noted that the ban follows Chinas earlier decision to place... More

Illumina slides as China bans imports of its gene sequencers

Investing.com -- Shares of Illumina (NASDAQ: ILMN) fell more than 4% in premarket trading on Tuesday after China imposed an immediate ban on the import of its gene sequencing instruments, escalating tensions in the ongoing US-China trade conflict.

Bank of America analysts noted that the ban follows Chinas earlier decision to... More

China Bans Illumina (ILMN) Sequencer Imports

China Bans Illumina (ILMN) Sequencer Imports

Illumina (ILMN) PT Lowered to $90 at Citi

Citi analyst Patrick Donnelly lowered the price target on Illumina (NASDAQ: ILMN) to $90.00 (from $130.00) while maintaining a Buy rating.... More

Citi Opens 90-Day Downside Short-term View on Illumina (ILMN)

Citi Opens 90-Day Downside Short-term View on Illumina (NASDAQ: ILMN).

The analyst comments "ILMN is facing multiple headwinds given recent developments. To start, ILMN was placed on Chinas "unreliable entities" list earlier this year, in Chinas response against new... More

HSBC downgrades Illumina on China risks, funding concerns

Investing.com -- HSBC downgraded Illumina Inc (NASDAQ: ILMN) to Hold from Buy and slashed its price target to $100 from $190, citing new headwinds from China, potential U.S. research funding cuts, and rising competition in the sequencing market.

Illuminas stock has fallen about 33% year-to-date, underperforming the broader market, and HSBC sees... More

HSBC Downgrades Illumina (ILMN) to Hold

(Updated - February 28, 2025 9:07 AM EST)

HSBC analyst Shubhangi Gupta downgraded Illumina (NASDAQ: ILMN) from Buy to Hold with a price target of $100.00 (from $190.00).

The analyst commented: "Downgrade the stock from Buy to Hold, cut TP to USD100 (from USD190): We use... More